ClinicalTrials.gg
CompletedNCT03482037Updated Jan 29, 2021

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

A Phase 1/2 interventional study of Rec 0/0438 1 mg or Rec 0/0438 2 mg and placebo in Neurogenic Detrusor Overactivity, sponsored by RECORDATI GROUP. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by RECORDATI GROUP · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Rec 0/0438 in subjects with neurogenic detrusor overactivity due to spinal cord injury

Read the detailed description

Multicentre, double-blind, randomised, parallel groups, placebo-controlled study to be conducted in specialized centres in Europe to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of two different doses of Rec 0/0438 in comparison with placebo, in subjects with neurogenic detrusor overactivity due to spinal cord injury.

02

Conditions studied

  • Neurogenic Detrusor Overactivity
03

In context

Lead sponsor

RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged ≥18 years and ≤65 years.
  • Female subjects must be either sterile or, if with , must have a pregnancy test negative and commit to the use of a highly effective method of (see Appendix 15.6) for the duration of the study, and until at least 1 month after the last dose of study medication. Male subjects must be willing to use male contraception (condom) to avoid pregnancies of their female partner of childbearing potential throughout the entire duration of the study, and for 3 months after the last dose of study medication.
  • Suffering from NDO due to SCI at upper motor neuron level (below C6) and emptying the bladder performing clear intermittent self-catheterization (CISC).
  • Subjects classified in group A, B, or C, of the ASIA (American Spinal Injury Association) impairment scale.
  • Stable therapy for NDO in the last thirty days (Subjects should maintain the therapy stable for the duration of the study).
  • At least 1 incontinence episode/day despite current treatment, according to what is reported in the Bladder Diary filled in by the subject.
  • Subjects with diastolic blood pressure values between 60 and 99 mmHg (both inclusive), and systolic blood pressure values between 90 and 159 mmHg (both inclusive). Blood pressure measurement must be performed in subjects with an empty bladder.
  • Subjects with stable concomitant medication treatment at baseline.
  • Written must be given by subjects before any study related procedures is performed.

Exclusion criteria

Exclusion Criteria:

  • Breastfeeding women.
  • Treatment with injection of botulinum toxin, unless in the opinion of the Investigator the bladder activity has returned to pre-treatment level.
  • Use of prohibited concomitant medications, such as drugs that could affect immunoassay testing (systemic : prednisone, budesonide, prednisolone; calcineurin inhibitors: cyclosporine, tacrolimus; mTOR inhibitors: sirolimus, everolimus; IMDH inhibitors: azathioprine, leflunomide, mycophenolate; biologics: abatacept, adalimumab, anakinra , certolizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, vedolizumab; monoclonal antibodies: basiliximab, daclizumab, muromonab) or initiation of therapy with drugs affecting lower urinary tract symptoms (such as alpha-blockers, tadalafil 5 mg oad). If already present at Screening visit, therapy with drugs affecting lower urinary tract symptoms must be maintained stable through the study period (Note: occasional treatment with PDE-5 inhibitors for erectile dysfunction should be avoided between Screening visit and Day 8 and between Day 25 and 28).
  • History of cerebro- or cardio-vascular diseases (, stroke, hypertensive encephalopathy, angina pectoris, MI, cardiac by-pass, CHF classes III and IV).
  • Uncontrolled type 1 or type 2 diabetes ( A1c >8 %).
  • Moderate to severe renal impairment (estimated \<60 mL/min by the Cockcroft-Gault equation).
  • Moderate to severe liver impairment (any liver function test: , ALT, GGT, >2.5 times the ).
  • Hemodynamically significant valve disease, including aortic stenosis or ventricular or supraventricular arrhythmia, heart rate >100 beats/min.
  • Clinically important abnormal laboratory findings during the run-in period, including: Haemoglobin \<10 g/dL; Serum Potassium >5.5 mmol/L; Serum Sodium \<132 mmol/L.
  • Symptomatic active urinary tract infection (i.e. cloudy and/or malodorous urine, chills, fever, increased muscle spasticity or increased autonomic dysreflexia, letargy, hypotension, malaise).
  • Evidence of any neoplastic disease.
  • History of allergy, or intolerance to drugs.
  • Participation in an drug study within 30 days prior to the screening assessment.
  • Any other diseases or conditions, that according to the Investigator's opinion, make the subject unable to comply with protocol requirements, or unable to complete the study or increases the risk to the subject or which prevents optimal participation in achieving the objectives of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Rec 0/0438

    Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks

    Drug: Rec 0/0438 1 mg or Rec 0/0438 2 mg

  • Placebo comparator
    Placebo

    Placebo, to be administered by intravesical instillation once daily for four weeks

    Drug: placebo

Interventions

  • DrugRec 0/0438 1 mg or Rec 0/0438 2 mg

    Each vial content will be administered via the catheter used for the self-catheterization

  • Drugplacebo

    Each vial content will be administered via the catheter used for the self-catheterization

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Treatment-emergent adverse events occurred with treatment with Rec 0/0438

    Time frame: Day 28

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Peak Plasma Concentration (Cmax)

    Time frame: Day 1 and Day 7

  2. Area Under the Curve (AUC)

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Day 1 and Day 7

  3. Change from baseline in Maximum Cystometric Capacity

    The volume at which uncontrollable voiding begins during filling Cystometry

    Time frame: Day 28

07

Study locations

9 sites
  • Recordati Investigative Site
    Praha, Czechia
  • Department of Urology, Academic hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne Universités
    Paris, 75013, France
  • Centre Hospitalier Lyon Sud Unité de Pharmacie Clinique Oncologique (essai clinique) Pavillon Marcel Bérard - Bât. 1G
    Pierre-Bénite, 69495, France
  • Recordati Investigative Site
    Rouen, France
  • Recordati Investigative Site
    Toulouse, France
  • Recordati Investigative Site
    Piaseczno, Poland
  • Recordati Investigative Site
    Rzeszów, Poland
  • Recordati Investigative Site
    Warszawa, Poland
  • Recordati Investigative Site
    Porto, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Mar 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 29, 2018
StartActual
Jun 7, 2018
Primary completionActual
Mar 27, 2019
CompletionActual
Mar 27, 2019
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03482037
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Jun 7, 2018
Primary completion
Mar 27, 2019
Completion
Mar 27, 2019
Last update
Jan 29, 2021

Study contacts

Francisco Cruz, M.D.
principal investigator · Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion